| Outcome                                      | Camostat mesilate | Placebo | Unadjusted hazard ratio (95%–CI) | Adjusted hazard ratio (95%–CI) | Camostat mesilate (n=137) | Placebo (n=68) |
|----------------------------------------------|-------------------|---------|----------------------------------|--------------------------------|---------------------------|----------------|
| Recovery - no. (%) [mITT]§                  | 129 (94)          | 62 (91) | 1·16 (0·85–1·57 [P=0·35])        | 1·18 (0·87–1·61 [P=0·28])    | 117/123 (95)             | 53/58 (91)     |
| Median to recovery (IQR) - days              | 5·0 (3·0–7·0)     | 6·0 (3·0–10·5) |                                  |                                |                          |                |
| Median duration of hospital admission (IQR) - days | 5·0 (3·0–7·0) | 5·5 (2·0–10·0) |                                  |                                |                          |                |
| 30-day mortality - no. (%)†                  | 8 (06)            | 4 (06) | 0·82 (0·24–2·79 [P=0·75])        |                                |                          |                |
| National Early Warning Score 2 at day 5 - median (IQR)* | 3 (1–4) | 2 (1–4) |                                  |                                |                          |                |
| Need for supplemental oxygen during admission - no. (%)‡† | 103 (75) | 52 (76) | 1·06 (0·76–1·47 [P=0·74])        |                                |                          |                |
| Need for invasive mechanical ventilation during admission - no. (%)‡* | 13 (09) | 3 (04) | 0·69 (0·44–1·44 [P=0·65])        |                                |                          |                |
| Intensive care unit admission – no. (%)‡| 14 (10)          | 8 (12) | 0·82 (0·35–1·96 [P=0·60])        | 0·80 (0·34–1·91 [P=0·61])    | 14 (10)                   | 7 (10)         |
| Intensive care unit admission/died – no. (%)‡ | 14 (10) | 12 (18) |                                |                                | 2·12 (0·81–5·55 [P=0·13]) |                |
| Readmission – no. (%)‡‡                       | 18 (13)          | 10 (15) |                                |                                |                          |                |

CI denotes confidence interval, IQR interquartile range, mITT modified Intention-to-treat, PP per-protocol.

§ Adjusted for oxygen supplemental at baseline, duration of symptoms prior to admission, receiving remdesivir and/or dexamethasone.

‡ Recovery hazard ratio greater than 1 indicate a benefit with camostat mesilate.

• Data on National Early Warning Score 2 were missing for 37 and 19 patients in the camostat mesilate and placebo group.

* One patient in each group required invasive mechanical ventilation on two separate intervals during the trial period.

† One patient in the placebo group were admitted to the intensive care unit twice during the trial period.

‡ Two patients in the placebo group were readmitted twice during the trial period.

---

CI denotes confidence interval, IQR interquartile range, mITT modified Intention-to-treat, PP per-protocol.

§ Adjusted for oxygen supplemental at baseline, duration of symptoms prior to admission, receiving remdesivir and/or dexamethasone.

‡ Recovery hazard ratio greater than 1 indicate a benefit with camostat mesilate.

• Data on National Early Warning Score 2 were missing for 37 and 19 patients in the camostat mesilate and placebo group.

* One patient in each group required invasive mechanical ventilation on two separate intervals during the trial period.

† One patient in the placebo group were admitted to the intensive care unit twice during the trial period.

‡ Two patients in the placebo group were readmitted twice during the trial period.